Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Director | July 10, 2026 | July 14, 2026 |
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Director | May 30, 2019 | June 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Exercise / conversion · Acquired 24,165 · Balance 24,165 Row 2 · 2026-07-10 · Sale · Disposed 24,165 · Balance 0 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.63 · Expires 2035-06-04 | Direct | 0 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Exercise / conversion · Disposed 24,165 · Balance 0 F3: Fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Fully vested.
Fulgent Genetics, Inc.
Report date May 30, 2019 · Filed June 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.81 · Expires 2029-05-30 | Direct | 5,000 |
Reported balance
After 2019-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-05-30 · Grant · Acquired 5,000 · Balance 5,000 F1: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 30, 2019, and 1/16th of such shares vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 30, 2019, and 1/16th of such shares vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 14, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 24,165 | $0.00 Strike: $26.63 | $0.00 |
DisclosureSEC source: 0001193125-26-303188 · ownership.xml · derivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,165 shares Expires 2035-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 24,165 | $75.16 | $1,816,241.40 |
DisclosureSEC source: 0001193125-26-303188 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 24,165 | $26.63 | $643,513.95 |
DisclosureSEC source: 0001193125-26-303188 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,310 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001684531-26-000002 · form4-06162026_090604.xml · derivative · entry 6 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,620 Underlying: Common Stock · 1,310 shares Expires 2033-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 654 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001684531-26-000002 · form4-06162026_090604.xml · derivative · entry 5 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 654 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested in 36 substantially equal monthly installments beginning on July 14, 2023. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,310 | $60.12 | $78,757.20 |
DisclosureSEC source: 0001684531-26-000002 · form4-06162026_090604.xml · nonDerivative · entry 4 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,310 | $12.59 | $16,492.90 |
DisclosureSEC source: 0001684531-26-000002 · form4-06162026_090604.xml · nonDerivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 654 | $60.12 | $39,318.48 |
DisclosureSEC source: 0001684531-26-000002 · form4-06162026_090604.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. Read SEC document |
| June 15, 2026 Filed Jun 16, 2026 21:07 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 654 | $3.72 | $2,432.88 |
DisclosureSEC source: 0001684531-26-000002 · form4-06162026_090604.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 9,354 | $0.00 Strike: $56.09 | $0.00 |
DisclosureSEC source: 0001193125-26-259691 · ownership.xml · derivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,354 Underlying: Common Stock · 9,354 shares Expires 2036-06-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 4, 2026, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 15,600 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0001193125-26-164013 · ownership.xml · derivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,600 shares Expires 2034-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 15,600 | $73.01 | $1,138,956.00 |
DisclosureSEC source: 0001193125-26-164013 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.99 to $73.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 17, 2026 Filed Apr 20, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 15,600 | $36.63 | $571,428.00 |
DisclosureSEC source: 0001193125-26-164013 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,310 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001193125-26-110831 · ownership.xml · derivative · entry 6 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,930 Underlying: Common Stock · 1,310 shares Expires 2033-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 654 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001193125-26-110831 · ownership.xml · derivative · entry 5 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 654 Underlying: Common Stock · 654 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,310 | $63.50 | $83,185.00 |
DisclosureSEC source: 0001193125-26-110831 · ownership.xml · nonDerivative · entry 4 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,310 | $12.59 | $16,492.90 |
DisclosureSEC source: 0001193125-26-110831 · ownership.xml · nonDerivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 654 | $63.50 | $41,529.00 |
DisclosureSEC source: 0001193125-26-110831 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 654 | $3.72 | $2,432.88 |
DisclosureSEC source: 0001193125-26-110831 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 10,491 | $0.00 Strike: $12.59 | $0.00 |
DisclosureSEC source: 0001193125-26-011756 · ownership.xml · derivative · entry 6 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,240 Underlying: Common Stock · 10,491 shares Expires 2033-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 654 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001193125-26-011756 · ownership.xml · derivative · entry 5 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,308 Underlying: Common Stock · 654 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 10,491 | $52.99 | $555,918.09 |
DisclosureSEC source: 0001193125-26-011756 · ownership.xml · nonDerivative · entry 4 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 10,491 | $12.59 | $132,081.69 |
DisclosureSEC source: 0001193125-26-011756 · ownership.xml · nonDerivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 654 | $44.16 | $28,880.64 |
DisclosureSEC source: 0001193125-26-011756 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 654 | $3.72 | $2,432.88 |
DisclosureSEC source: 0001193125-26-011756 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 5,903 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001193125-25-237104 · ownership.xml · derivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 5,903 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 5,903 | $43.99 | $259,672.97 |
DisclosureSEC source: 0001193125-25-237104 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| October 09, 2025 Filed Oct 10, 2025 20:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 5,903 | $3.72 | $21,959.16 |
DisclosureSEC source: 0001193125-25-237104 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,903 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:38 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 12,755 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001193125-25-225133 · ownership.xml · derivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,755 shares Expires 2031-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:38 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 12,755 | $39.19 | $499,868.45 |
DisclosureSEC source: 0001193125-25-225133 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.99 to $39.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 20:38 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 12,755 | $1.82 | $23,214.10 |
DisclosureSEC source: 0001193125-25-225133 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 11:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 3,574 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001193125-25-210015 · ownership.xml · derivative · entry 6 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,755 Underlying: Common Stock · 3,574 shares Expires 2031-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 11:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 3,574 | $38.99 | $139,350.26 |
DisclosureSEC source: 0001193125-25-210015 · ownership.xml · nonDerivative · entry 4 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 11:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 3,574 | $1.82 | $6,504.68 |
DisclosureSEC source: 0001193125-25-210015 · ownership.xml · nonDerivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 11:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 19,112 | $0.00 Strike: $1.82 | $0.00 |
DisclosureSEC source: 0001193125-25-210015 · ownership.xml · derivative · entry 5 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,329 Underlying: Common Stock · 19,112 shares Expires 2031-07-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 11:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 19,112 | $39.01 | $745,559.12 |
DisclosureSEC source: 0001193125-25-210015 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.99 to $39.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 18, 2025 Filed Sep 22, 2025 11:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 19,112 | $1.82 | $34,783.84 |
DisclosureSEC source: 0001193125-25-210015 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,112 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 27,015 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-113556 · ownership.xml · derivative · entry 6 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,015 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 3,113 | $33.22 | $103,413.86 |
DisclosureSEC source: 0000950170-25-113556 · ownership.xml · nonDerivative · entry 5 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.06 to $33.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 7,465 | $32.64 | $243,657.60 |
DisclosureSEC source: 0000950170-25-113556 · ownership.xml · nonDerivative · entry 4 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,113 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.06 to $33.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 4,095 | $31.42 | $128,664.90 |
DisclosureSEC source: 0000950170-25-113556 · ownership.xml · nonDerivative · entry 3 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,578 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.01 to $31.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 12,342 | $30.47 | $376,060.74 |
DisclosureSEC source: 0000950170-25-113556 · ownership.xml · nonDerivative · entry 2 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,673 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 20:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 27,015 | $0.60 | $16,209.00 |
DisclosureSEC source: 0000950170-25-113556 · ownership.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 21:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantDirector Stock Option (right to buy) · Derivative | 24,165 | $0.00 Strike: $26.63 | $0.00 |
DisclosureSEC source: 0000950170-25-083238 · ownership.xml · derivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,165 Underlying: Common Stock · 24,165 shares Expires 2035-06-04 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following June 5, 2025, the date of grant (or, in the event the next annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of this stock option will vest on the date of such annual meeting of the Issuer's stockholders), subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 21:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113299 · ownership.xml · derivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 15,600 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following October 4, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.81 | $0.00 |
DisclosureSEC source: 0001209191-19-033858 · doc4.xml · derivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-05-30 F1 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 30, 2019, and 1/16th of such shares vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date. Read SEC document |
| May 18, 2018 Filed May 21, 2018 20:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0001209191-18-031806 · doc4.xml · derivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2028-05-18 F1 · derivative.exercise_date: The shares subject to the option vest over a period of four years, with 1/4th of such shares vesting 12 months after May 18, 2018, and 1/16th of such shares vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date. Read SEC document |
| May 16, 2017 Filed Jun 13, 2017 00:24 UTC Amendment | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-039312 · doc4a.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents an award of 2,000 restricted stock units ("RSUs") granted to Dr. Mulay in connection with his reelection as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after May 16, 2017, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date. F2 · shares: This amendment is being filed because the name of the reporting person was incorrect in the Form 4 as originally filed. This line item is being re-reported in this amendment in order to gain access to the filing system for purposes of filing this amendment. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 20:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147291 · doc4.xml · nonDerivative · entry 1 Mulay James · CIK 0001684531 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · shares: Represents an award of 8,000 restricted stock units ("RSUs") granted to Dr. Mulay in connection with his appointment as a director of the Issuer. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest over a period of four years, with 1/4th of the shares subject to the RSUs vesting 12 months after September 28, 2016, and 1/16th of the remaining shares subject to the RSUs vesting at the end of every three-month period over the 36 months thereafter, subject to Dr. Mulay's continued service for the Issuer on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.